Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 31st total of 4,440,000 shares. Based on an average daily volume of 400,900 shares, the short-interest ratio is currently 12.0 days. Approximately 19.6% of the company's stock are sold short.

Arcturus Therapeutics Stock Up 11.7 %

ARCT traded up $1.88 during midday trading on Wednesday, hitting $17.93. 401,908 shares of the company traded hands, compared to its average volume of 405,948. The company's 50-day moving average is $17.21 and its 200 day moving average is $19.30. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The firm has a market capitalization of $485.72 million, a PE ratio of -8.08 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. During the same quarter in the previous year, the firm posted ($0.61) EPS. On average, sell-side analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ARCT. BTIG Research started coverage on Arcturus Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $41.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Finally, HC Wainwright restated a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $61.60.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company's stock valued at $202,000 after buying an additional 846 shares during the period. nVerses Capital LLC purchased a new position in shares of Arcturus Therapeutics during the 3rd quarter worth $42,000. China Universal Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock valued at $121,000 after acquiring an additional 2,038 shares during the period. Nordea Investment Management AB increased its holdings in Arcturus Therapeutics by 3.7% in the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company's stock worth $1,097,000 after acquiring an additional 2,335 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company's stock worth $4,587,000 after acquiring an additional 3,224 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.